References
  1. Eleutério SJ, Senerchia AA, Almeida MT, et al. Osteosarcoma in patients younger than 12 years old without metastases have similar prognosis as adolescent and young adults. Pediatr Blood Cancer. 2015;62(7):1209-1213. doi:10.1002/pbc.25459
  2. Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134(3):281-297. doi:10.1007/s00432-007-0330-x
  3. Bajpai J, Chandrasekharan A, Talreja V, et al. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen ’OGS-12’. Eur J Cancer. 2017;85:49-58. doi:10.1016/j.ejca.2017.08.013
  4. Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer. 1979;43(6):2178-2181. doi:10.1002/1097-0142(197906)43:6<2178::aid-cncr2820430603>3.0.co;2-9
  5. Li X, Ashana AO, Moretti VM, Lackman RD. The relation of tumour necrosis and survival in patients with osteosarcoma. Int Orthop. 2011;35(12):1847-1853. doi:10.1007/s00264-011-1209-7
  6. Bacci G, Mercuri M, Longhi A, et al. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer. 2005;41(14):2079-2085. doi:10.1016/j.ejca.2005.03.036
  7. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study Group. J Clin Oncol. 2000;18(17):3108-3114. doi:10.1200/JCO.2000.18.17.3108
  8. Balamuth NJ, Womer RB. Ewing’s sarcoma. Lancet Oncol. 2010;11(2):184-192. doi:10.1016/S1470-2045(09)70286-4
  9. Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with Ewing’s sarcoma using the surveillance, epidemiology, and end results (SEER) program database. Cancer Epidemiol. 2015;39(2):189-195. doi:10.1016/j.canep.2014.12.012
  10. Bajpai J, Panda GS, Chandrasekharan A, et al. Adolescent-adult nonmetastatic Ewing sarcoma-Experience from a large developing country. Pediatr Blood Cancer. 2021;68(9):e29081. doi:10.1002/pbc.29081
  11. Wunder JS, Paulian G, Huvos AG, et al. The histological response to chemotherapy as a predictor of the oncological outcome of operative treatment of Ewing sarcoma. J Bone Joint Surg Am. 1998;80(7):1020-1033. doi:10.2106/00004623-199807000-00011
  12. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992;10(1):5-15. doi:10.1200/JCO.1992.10.1.5
  13. Schwartz CL, Gorlick R, Teot L, et al. Multiple drug resistance in osteogenic sarcoma: INT0133 from the Children’s Oncology Group. J Clin Oncol. 2007;25(15):2057-2062. doi:10.1200/JCO.2006.07.7776
  14. Bielack S, Kempf-Bielack B, Schwenzer D, et al. Neoadjuvante Therapie des lokalisierten Osteosarkoms der Extremitäten. Erfahrungen der Cooperativen Osteosarkomstudiengruppe COSS an 925 Patienten [Neoadjuvant therapy for localized osteosarcoma of extremities. Results from the Cooperative osteosarcoma study group COSS of 925 patients]. Klin Padiatr. 1999;211(4):260-270. doi:10.1055/s-2008-1043798
  15. Meyer WH, Pratt CB, Poquette CA, et al. Carboplatin/ifosfamide window therapy for osteosarcoma: results of the St Jude Children’s Research Hospital OS-91 trial. J Clin Oncol. 2001;19(1):171-182. doi:10.1200/JCO.2001.19.1.171
  16. Thorpe WP, Reilly JJ, Rosenberg SA. Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy. Cancer. 1979;43(6):2178-2181. doi:10.1002/1097-0142(197906)43:6<2178::aid-cncr2820430603>3.0.co;2-9
  17. Jin Q, Xie X, Yao H, et al. Clinical Significance of the Radiological Relationship between the Tumor and the main blood vessels in Enneking IIB Osteosarcoma of the extremities. J Cancer . 2020;11(11):3235-3245. Published 2020 Mar 5. doi:10.7150/jca.42341
  18. Rodríguez-Galindo C, Liu T, Krasin MJ, et al. Analysis of prognostic factors in ewing sarcoma family of tumors: review of St. Jude Children’s Research Hospital studies. Cancer. 2007;110(2):375-384. doi:10.1002/cncr.22821
  19. Stahl M, Ranft A, Paulussen M, et al. Risk of recurrence and survival after relapse in patients with Ewing sarcoma. Pediatr Blood Cancer. 2011;57(4):549-553. doi:10.1002/pbc.23040
  20. Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother. 2001;13(3):324-330. doi:10.1179/joc.2001.13.3.324
  21. Sukumaran RK, Rajeshwari B, Sugath S, Chellappan SG, Thankamony P, Parukuttyamma K. Methotrexate Free Chemotherapy and Limb Salvage Surgery for Paediatric Osteosarcoma in India. Indian J Orthop. 2018;52(1):58-64. doi:10.4103/ortho.IJOrtho_195_17
  22. Dharanikota A, Arjunan R, Dasappa A. Factors Affecting Prognosis and Survival in Extremity Osteosarcoma. Indian J Surg Oncol. 2021;12(1):199-206. doi:10.1007/s13193-020-01277-2
  23. Ganguly S, Sasi A, Khan SA, et al. Formulation and validation of a baseline prognostic score for osteosarcoma treated uniformly with a non-high dose methotrexate-based protocol from a low middle income healthcare setting: a single centre analysis of 594 patients. Front Oncol. 2023;13:1148480. Published 2023 Apr 28. doi:10.3389/fonc.2023.1148480
  24. Petrilli AS, Brunetto AL, Cypriano Mdos S, et al. Fifteen Years’ Experience of the Brazilian Osteosarcoma Treatment Group (BOTG): A Contribution from an Emerging Country. J Adolesc Young Adult Oncol. 2013;2(4):145-152. doi:10.1089/jayao.2013.0012
  25. Song K, Song J, Chen F, Lin K, Ma X, Jiang J. Prognostic nomograms for predicting overall and cancer-specific survival of high-grade osteosarcoma patients. J Bone Oncol. 2018;13:106-113. Published 2018 Oct 4. doi:10.1016/j.jbo.2018.09.012
  26. Lu S, Wang Y, Liu G, et al. Construction and validation of nomogram to predict distant metastasis in osteosarcoma: a retrospective study. J Orthop Surg Res. 2021;16(1):231. Published 2021 Mar 30. doi:10.1186/s13018-021-02376-8
  27. Yang QK, Lai QY, Wang Y, Wang Y, Yao ZX, Zhang XJ. Establishment and validation of prognostic nomograms to predict overall survival and cancer-specific survival for patients with osteosarcoma. Neoplasma. 2021;68(2):434-446. doi:10.4149/neo_2020_200617N639
  28. Zhang J, Yang J, Wang HQ, et al. Development and validation of a nomogram for osteosarcoma-specific survival: A population-based study. Medicine (Baltimore) . 2019;98(23):e15988. doi:10.1097/MD.0000000000015988
  29. Gao F, Zhou Y, Zhao R, Ren Y. Establishing a novel prognostic tool for Ewing sarcoma patients: Surveillance, Epidemiology, and End Results database analysis. Medicine (Baltimore). 2020;99(46):e23050. doi:10.1097/MD.0000000000023050
  30. Zhang J, Pan Z, Yang J, Yan X, Li Y, Lyu J. A nomogram for determining the disease-specific survival in Ewing sarcoma: a population study. BMC Cancer. 2019;19(1):667. Published 2019 Jul 5. doi:10.1186/s12885-019-5893-9
  31. Zhou Q, Wu ZY, Lin ZQ. A nomogram to predict prognosis in Ewing sarcoma of bone. J Bone Oncol. 2019;15:100223. Published 2019 Feb 12. doi:10.1016/j.jbo.2019.100223
  32. Bosma SE, Lancia C, Rueten-Budde AJ, et al. Easy-to-use clinical tool for survival estimation in Ewing sarcoma at diagnosis and after surgery. Sci Rep. 2019;9(1):11000. Published 2019 Jul 29. doi:10.1038/s41598-019-46721-8
  33. Zhou Z, Wang J, Fang L, Ma J, Guo M. A nomogram for predicting overall survival in patients with Ewing sarcoma: a SEER-based study. BMC Musculoskelet Disord. 2020;21(1):737. Published 2020 Nov 12. doi:10.1186/s12891-020-03706-3
  34. Shi J, Yang J, Ma X, Wang X. Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study. J Orthop Surg Res. 2020;15(1):88. Published 2020 Mar 4. doi:10.1186/s13018-020-01607-8
  35. Nataraj V, Batra A, Rastogi S, et al. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients. J Surg Oncol. 2015;112(6):662-668. doi:10.1002/jso.24045
  36. Wagner MJ, Livingston JA, Patel SR, Benjamin RS. Chemotherapy for Bone Sarcoma in Adults. J Oncol Pract. 2016;12(3):208-216. doi:10.1200/JOP.2015.009944
  37. Bajpai J, Chandrasekharan A, Simha V, et al. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center. J Glob Oncol. 2018;4:1-10. doi:10.1200/JGO.17.00137
  38. Mailankody S, Kumar VS, Khan SA, Banavali SD, Bajpai J. Resource-appropriate selection of osteosarcoma treatment protocols in low- and middle-income countries. Pediatr Blood Cancer. 2022;69(3):e29540. doi:10.1002/pbc.29540
LEGENDS:
Figure 1: Figure 1 is a CONSORT diagram depicting the number of patients analyzed in the current study
Figure 2A[i]: Figure 2A[i] is a Kaplan-Meier curve depicting event-free survival for the patients with non-metastatic osteosarcoma: derivation cohort (n=342)
Figure 2A[ii]: Figure 2A[ii] is a Kaplan-Meier curve depicting event-free survival for the patients with non-metastatic osteosarcoma: derivation cohort (n=158)
Figure 2A[iii]: Figure 2A[iii] is a Kaplan-Meier curve depicting event-free survival for the patients with non-metastatic osteosarcoma: derivation cohort (n=500)
Figure 2B: Figure 2B is a nomogram depicting the prognostic model for non-metastatic Ewing’s Sarcoma
Figure 2C: Figure 2C is a nomogram depicting the prognostic model for metastatic osteosarcoma
Figure 2D: Figure 2D is a nomogram depicting the prognostic model for metastatic Ewing’s Sarcoma